|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2006-3-3
|
|
pubmed:abstractText |
In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV) demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir (LPV/RTV) over 48 weeks in treatment-experienced patients. Results of extended follow-up to 96 weeks are presented.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenine,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Didanosine,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Lopinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidinones,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Ritonavir,
http://linkedlifedata.com/resource/pubmed/chemical/Saquinavir,
http://linkedlifedata.com/resource/pubmed/chemical/atazanavir,
http://linkedlifedata.com/resource/pubmed/chemical/tenofovir
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
pubmed-author:CocoJeffreyJ,
pubmed-author:DeJesusEdwinE,
pubmed-author:GrinsztejnBeatrizB,
pubmed-author:JohnsonMargaretM,
pubmed-author:LazzarinAdrianoA,
pubmed-author:LichtensteinKennethK,
pubmed-author:McLarenColinC,
pubmed-author:OdeshooLindaL,
pubmed-author:RightmireAnnaA,
pubmed-author:RodriguezClaudiaC,
pubmed-author:WirtzVictoriaV
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
21
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
711-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16514301-Adenine,
pubmed-meshheading:16514301-Adult,
pubmed-meshheading:16514301-Anti-HIV Agents,
pubmed-meshheading:16514301-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:16514301-Didanosine,
pubmed-meshheading:16514301-Drug Administration Schedule,
pubmed-meshheading:16514301-Drug Therapy, Combination,
pubmed-meshheading:16514301-Female,
pubmed-meshheading:16514301-HIV Infections,
pubmed-meshheading:16514301-HIV-1,
pubmed-meshheading:16514301-Humans,
pubmed-meshheading:16514301-Lipids,
pubmed-meshheading:16514301-Lopinavir,
pubmed-meshheading:16514301-Male,
pubmed-meshheading:16514301-Oligopeptides,
pubmed-meshheading:16514301-Phosphonic Acids,
pubmed-meshheading:16514301-Pyridines,
pubmed-meshheading:16514301-Pyrimidinones,
pubmed-meshheading:16514301-RNA, Viral,
pubmed-meshheading:16514301-Ritonavir,
pubmed-meshheading:16514301-Saquinavir,
pubmed-meshheading:16514301-Time Factors,
pubmed-meshheading:16514301-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
|
|
pubmed:affiliation |
Royal Free Hospital, London, UK. margaret.johnson@royalfree.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
